These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27065001)

  • 1. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: results from the EPATH randomized, placebo-controlled trial.
    Tomaschitz A; Verheyen N; Meinitzer A; Pieske B; Belyavskiy E; Brussee H; Haas J; März W; Pieske-Kraigher E; Verheyen S; Ofner-Ziegenfuss L; Hartaigh BÓ; Schwetz V; Aberer F; Grübler M; Lang F; Alesutan I; Voelkl J; Gaksch M; Horina JH; Dimai HP; Rus-Machan J; Stiegler C; Ritz E; Fahrleitner-Pammer A; Pilz S
    J Hypertens; 2016 Jul; 34(7):1347-56. PubMed ID: 27065001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Parathyroid hormone, aldosterone-to-renin ratio and fibroblast growth factor-23 as determinants of nocturnal blood pressure in primary hyperparathyroidism: the eplerenone in primary hyperparathyroidism trial.
    Verheyen N; Fahrleitner-Pammer A; Pieske B; Meinitzer A; Belyavskiy E; Wetzel J; Gaksch M; Grübler MR; Catena C; Sechi LA; Van Ballegooijen AJ; Brandenburg VM; Scharnagl H; Perl S; Brussee H; März W; Pilz S; Tomaschitz A
    J Hypertens; 2016 Sep; 34(9):1778-86. PubMed ID: 27379537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mineralocorticoid Receptor Blockers and Aldosterone to Renin Ratio: A Randomized Controlled Trial and Observational Data.
    Pilz S; Trummer C; Verheyen N; Schwetz V; Pandis M; Aberer F; Grübler MR; Meinitzer A; Bachmann A; Voelkl J; Alesutan I; Catena C; Sechi LA; März W; Obermayer-Pietsch B; Tomaschitz A
    Horm Metab Res; 2018 May; 50(5):375-382. PubMed ID: 29723896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
    Weinberger MH; Roniker B; Krause SL; Weiss RJ
    Am J Hypertens; 2002 Aug; 15(8):709-16. PubMed ID: 12160194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients.
    Flack JM; Oparil S; Pratt JH; Roniker B; Garthwaite S; Kleiman JH; Yang Y; Krause SL; Workman D; Saunders E
    J Am Coll Cardiol; 2003 Apr; 41(7):1148-55. PubMed ID: 12679215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction.
    Pitt B; Remme W; Zannad F; Neaton J; Martinez F; Roniker B; Bittman R; Hurley S; Kleiman J; Gatlin M;
    N Engl J Med; 2003 Apr; 348(14):1309-21. PubMed ID: 12668699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of the novel selective aldosterone blocker eplerenone using ambulatory and clinical blood pressure in patients with systemic hypertension.
    White WB; Carr AA; Krause S; Jordan R; Roniker B; Oigman W
    Am J Cardiol; 2003 Jul; 92(1):38-42. PubMed ID: 12842242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension.
    White WB; Duprez D; St Hillaire R; Krause S; Roniker B; Kuse-Hamilton J; Weber MA
    Hypertension; 2003 May; 41(5):1021-6. PubMed ID: 12682082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of eplerenone on parathyroid hormone levels in patients with primary hyperparathyroidism: a randomized, double-blind, placebo-controlled trial.
    Tomaschitz A; Fahrleitner-Pammer A; Pieske B; Verheyen N; Amrein K; Ritz E; Kienreich K; Horina JH; Schmidt A; Kraigher-Krainer E; Colantonio C; Meinitzer A; Pilz S
    BMC Endocr Disord; 2012 Sep; 12():19. PubMed ID: 22974443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.
    Verheyen N; Grübler MR; Meinitzer A; Trummer C; Schwetz V; Amrein K; Dimai HP; März W; Catena C; von Lewinski D; Voelkl J; Alesutan I; Fahrleitner-Pammer A; Brussee H; Pilz S; Tomaschitz A
    Bone; 2017 Dec; 105():212-217. PubMed ID: 28918310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The efficacy and safety of the novel aldosterone antagonist eplerenone in children with hypertension: a randomized, double-blind, dose-response study.
    Li JS; Flynn JT; Portman R; Davis I; Ogawa M; Shi H; Pressler ML
    J Pediatr; 2010 Aug; 157(2):282-7. PubMed ID: 20400095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Sudano I; Naegele M; Roas S; Périat D; Frank M; Kouroedov A; Noll G; Lüscher TF; Enseleit F; Ruschitzka F; Flammer AJ
    Clin Cardiol; 2016 May; 39(5):285-90. PubMed ID: 26991772
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis.
    Pelliccia F; Patti G; Rosano G; Greco C; Gaudio C
    Int J Cardiol; 2014 Nov; 177(1):219-28. PubMed ID: 25499383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spironolactone versus eplerenone for the treatment of idiopathic hyperaldosteronism.
    Karagiannis A; Tziomalos K; Papageorgiou A; Kakafika AI; Pagourelias ED; Anagnostis P; Athyros VG; Mikhailidis DP
    Expert Opin Pharmacother; 2008 Mar; 9(4):509-15. PubMed ID: 18312153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial.
    Walsh M; Manns B; Garg AX; Bueti J; Rabbat C; Smyth A; Tyrwhitt J; Bosch J; Gao P; Devereaux PJ; Wald R
    Clin J Am Soc Nephrol; 2015 Sep; 10(9):1602-8. PubMed ID: 26138259
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R; McMurray JJ; Swedberg K; van Veldhuisen DJ; Krum H; Pocock SJ; Shi H; Vincent J; Rossignol P; Zannad F; Pitt B;
    J Am Coll Cardiol; 2013 Oct; 62(17):1585-93. PubMed ID: 23810881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
    Savoia C; Touyz RM; Amiri F; Schiffrin EL
    Hypertension; 2008 Feb; 51(2):432-9. PubMed ID: 18195160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.